Stock Market News
PureTech affiliate Alivio granted two key US patents
Clinical-stage biopharmaceutical company PureTech Health announced on Tuesday that its affiliate Alivio Therapeutics has been granted two key patents broadly covering its inflammation-targeting technology platform.
The London-listed firm said Alivio's newest patents issued by the United States Patent and Trademark Office - numbers 9,962,339 and 9,974,859 - broadly covered compositions of matter and other aspects of the inflammation-targeting microfibre materials with embedded molecules of interest.
It said the patents lay a "strong foundation" for Alivio to expand its intellectual property portfolio for the unique technology platform.
Both patents were exclusively licensed by Alivio from Brigham and Women's Hospital and the Massachusetts Institute of Technology.
"PureTech's mission is to pioneer new categories of medicine that address serious chronic diseases in a highly targeted manner," said PureTech chief of research and strategy Eric Elenko.
"One area of focus for us is autoimmune disease, such as inflammatory bowel disease and other inflammatory conditions, and Alivio is pioneering inflammation-targeting technology to offer safe and effective treatment options for patients living with these challenging disorders.
"These new patents validate the uniqueness of Alivio's approach and are foundational to this affiliate's growing pipeline of targeted immunomodulation opportunities.£
PureTech noted that in April, a preclinical study of Alivio's technology platform was published in Nature Communications, demonstrating proof-of-concept that an immunomodulatory drug - administered locally using the Alivio inflammation-targeting technology - substantially reduced measures of arthritis disease activity, with a 5.7-fold improvement in the disease clinical score versus control, as compared to only 1.4-fold for the free drug.
In July last year, Alivio presented data for product candidate ALV-107, showing durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose, in a validated preclinical model for the treatment of interstitial cystitis/bladder pain syndrome.
The London-listed firm said Alivio's newest patents issued by the United States Patent and Trademark Office - numbers 9,962,339 and 9,974,859 - broadly covered compositions of matter and other aspects of the inflammation-targeting microfibre materials with embedded molecules of interest.
It said the patents lay a "strong foundation" for Alivio to expand its intellectual property portfolio for the unique technology platform.
Both patents were exclusively licensed by Alivio from Brigham and Women's Hospital and the Massachusetts Institute of Technology.
"PureTech's mission is to pioneer new categories of medicine that address serious chronic diseases in a highly targeted manner," said PureTech chief of research and strategy Eric Elenko.
"One area of focus for us is autoimmune disease, such as inflammatory bowel disease and other inflammatory conditions, and Alivio is pioneering inflammation-targeting technology to offer safe and effective treatment options for patients living with these challenging disorders.
"These new patents validate the uniqueness of Alivio's approach and are foundational to this affiliate's growing pipeline of targeted immunomodulation opportunities.£
PureTech noted that in April, a preclinical study of Alivio's technology platform was published in Nature Communications, demonstrating proof-of-concept that an immunomodulatory drug - administered locally using the Alivio inflammation-targeting technology - substantially reduced measures of arthritis disease activity, with a 5.7-fold improvement in the disease clinical score versus control, as compared to only 1.4-fold for the free drug.
In July last year, Alivio presented data for product candidate ALV-107, showing durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose, in a validated preclinical model for the treatment of interstitial cystitis/bladder pain syndrome.
Related share prices |
---|
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price